Literature DB >> 8166268

Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.

J M Barragán1, R E Rodríguez, E Blázquez.   

Abstract

This study was designed to determine the effects of glucagon-like peptides (GLP) on arterial blood pressure and heart rate. Although glucagon caused a minimal effect and GLP-1-(1-37) produced a moderate increase of both systolic and diastolic blood pressure, GLP-1-(7-36) amide induced the greatest increases in both parameters. Systolic and diastolic blood pressure and heart rate values increased when doses of the peptides were increased. By contrast, GLP-2 did not modify either arterial blood pressure or heart rate values. To determine whether the effects of GLP-1-(7-36) amide were mediated through catecholamines, the rats were pretreated with reserpine, propranolol, or phentolamine before administration of the peptide. In these three experimental groups, GLP-1-(7-36) amide increases mean arterial blood pressure and heart rate to the same level or even greater than that observed in nonpretreated rats. These findings indicate that GLP-1-(7-36) amide significantly increases arterial blood pressure and heart rate and that these effects are not mediated through catecholamines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166268     DOI: 10.1152/ajpendo.1994.266.3.E459

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  52 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  The incretin system and cardiometabolic disease.

Authors:  Paul E Szmitko; Lawrence A Leiter; Subodh Verma
Journal:  Can J Cardiol       Date:  2010-02       Impact factor: 5.223

3.  Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.

Authors:  Abu Sufiun; Kazi Rafiq; Yoshihide Fujisawa; Asadur Rahman; Hirohito Mori; Daisuke Nakano; Hiroyuki Kobori; Koji Ohmori; Tsutomu Masaki; Masakazu Kohno; Akira Nishiyama
Journal:  Hypertens Res       Date:  2015-01-15       Impact factor: 3.872

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Authors:  Thomas Jax
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

6.  Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction.

Authors:  Rajesh Kumar Suman; Manjusha K Borde; Ipseeta Ray Mohanty; Ujwala Maheshwari; Y A Deshmukh
Journal:  J Clin Diagn Res       Date:  2016-03-01

Review 7.  Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.

Authors:  Paul Stranges; Ujjaini Khanderia
Journal:  Ther Adv Drug Saf       Date:  2012-08

8.  Functional characterization of N-terminally GFP-tagged GLP-1 receptor.

Authors:  Aljosa Bavec; Alenka Licar
Journal:  J Biomed Biotechnol       Date:  2009-10-22

9.  Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.

Authors:  Jens Kristensen; Ulrik M Mortensen; Morten Schmidt; Peter Haubjerg Nielsen; Torsten Toftegaard Nielsen; Michael Maeng
Journal:  BMC Cardiovasc Disord       Date:  2009-07-23       Impact factor: 2.298

10.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.

Authors:  Anne Gill; Byron J Hoogwerf; Jude Burger; Simon Bruce; Leigh Macconell; Ping Yan; Daniel Braun; Joseph Giaconia; James Malone
Journal:  Cardiovasc Diabetol       Date:  2010-01-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.